Precision radiation oncology: Achievements and challenges
Jinming Yu,Ligang Xing
DOI: https://doi.org/10.1002/pro6.8
2017-01-01
Precision Radiation Oncology
Abstract:In the past decade, clinical practice and research models have been developed from evidence-based medicine into individualized medicine, and then precision medicine. In his State of the Union Address on 20 January 2015, the President of the USA, Barack Obama, announced his intention to launch a Precision Medicine Initiative “to bring us closer to curing diseases like cancer and diabetes, and to give all of us access to the personalized information we need to keep ourselves and our families healthier.” After that, many countries, including China, have implemented serial precision medicine projects. From the view of cancer care, the aim of precision medicine is to select the best treatment option for each patient at the appropriate time in the natural history of the disease, based on understanding the molecular makeup of the tumor, with the ultimate objective of improving patient survival and quality of life.1, 2 Radiation oncology is one of the most important treatment facilities in the management of malignant tumors. Radiation therapy is based heavily on fields such as physics, mathematics, computer science, and electrical engineering, as well as radiation biology, making it a truly interdisciplinary field, unparalleled by many other clinical disciplines. Now radiotherapy can be applied safely, precisely, and efficiently. Tumor control and the probability of cure have been significantly improved for many cancer patients. Precision radiation oncology is not a new concept. Over 10 years ago, we published a monograph “Precision Radiation Oncology” in Chinese, in which we defined it as: “precise simulation, planning and delivery of conformal and high dose to the target volume to improve local control and therapeutic ratio”.3 At that time, the concept mainly represented the improved precision in physics. Recent biotechnological advances have led to an explosion of disease-relevant molecular information, with the potential for greatly advancing patient care. However, progress brings new challenges, and the success of precision radiation oncology will depend more and more on rapid scientific developments in biology. Recent advances in radiation oncology have originated from physics and engineering sciences, such as 3-D conformal radiotherapy, 3-D brachytherapy, stereotactic radiotherapy, intensity-modulated radiation therapy (IMRT), image-guided and adaptive radiotherapy, and radiotherapy with charged particles (proton and carbon ion). Using 3-D conformal radiotherapy and IMRT, we are able to conform the radiation to the target volume. We are even able to sculpt the dose within the target volume. IMRT solves the problem of irradiating complex target volumes close to critical structures. IMRT is successfully applied in most modern clinics for head and neck cancer, prostate cancer, and many other cancer treatments. In addition, IMRT offers the opportunity to reconsider radiation fractionation, as individual fraction sizes can be greatly increased. In the past 10 years, there has been very rapid growth in clinical research and applications of stereotactic ablative radiotherapy or stereotactic body radiation therapy for various body sites. With the advancement of image-guided technologies, the use of stereotactic body radiation therapy has been expanded from the lung, liver, and spine to the head and neck, kidney, prostate, adrenal gland, and female reproductive tract. Evidence across multiple tumor sites has been extremely positive for local control and similar or reduced toxicity. With a 3-year local control rate of 88–100%, overall survival of 60–70%, and limited toxicity, stereotactic body radiation therapy has emerged as standard of care for medically inoperable stage I NSCLC (non-small cell lung cancer), and might even challenge surgery in operable patients.4, 5 Target delineation is one of the key steps in precise radiotherapy. With wide application of computed tomography, high-resolution magnetic resonance imaging, positron emission tomography (PET), and image fusion technology in radiotherapy, we can distinguish the border of the tumor more accurately from adjacent structures. The availability of clinical PET is increasing rapidly around the world. The advantages of PET/computed tomography include precise localization of suspicious tracer uptake, higher sensitivity and specificity, more accurate quantification of tracer uptake, and improved radiotherapy planning. Target delineation guided by 18F-fluorodeoxyglucose PET/computed tomography imaging has become one of the standard treatment modalities for NSCLC and many other cancers. Representative parameters including standard uptake value and tumor metabolic target volume derived from PET imaging using 18F-fluorodeoxyglucose and other tracers might contribute to individualized delineation and outcome prediction.6 A longstanding goal of radiation therapy has been to make the radiation dose conform as closely as possible to the target volume while minimizing the dose to normal tissues. Considerations of radiation dose have conventionally been arrived at more often by the tolerance of the normal tissues than by determining a dose consistent with the high probability of curing the tumor. The precision in physics will still be a hot topic. New treatment systems are being developed and improved. Proton therapy has received more and more attention. However, some trials in prostate and lung cancer with negative results have been received with caution. Accumulation of clinical evidence is ongoing.7 The proper dose to maximize tumor control is now being reconsidered. It will be true that different types of tumors require very different fractionation schemes to achieve optimal benefit. Importantly, the use of few fractions of radiation delivery would undoubtedly result in biological effects very different from conventionally fractionated radiation. Despite the evolution of hypofractionation strategies and the concomitant radiobiological paradigm shift, many questions remain as to how best to maximize the radiobiological advantage, select patients, select hypofractionation schemes, and apply constraints to ensure the prevention of long-term normal tissue effects. Radiotherapy for advanced staged cancer is now being changed. With early diagnosis and molecular imaging approaches, we can identify such patients with a relatively limited number of metastases, and then perhaps these oligometastases can be individually treated with the goal of cure, or at least, long-term control. With the increasing effectiveness of systemic treatment as novel molecular targeted and chemotherapy agents, the oligometastatic state might also be achieved. These residual tumors could be eradicated by irradiation using hypofractionation with very precise immobilization and tumor conformality. Well-designed clinical trials, which incorporate molecular and imaging end-points, are being carried out to elucidate the efficacy. Epithelial growth factor receptor (EGFR) is the most important driven gene in Asian lung cancer patients. Targeted treatment with EGFR tyrosine kinase inhibitors for EGFR mutation lung cancer was one of the basics for cancer precise medicine. Building on the preclinical rationale that inhibitors of EGFR are strong radiation sensitizers, clinical trials incorporating the EGFR inhibitors and radiotherapy have been carried out. Clinical trials of EGFR inhibitors given concurrently with thoracic radiotherapy in locally advanced NSCLC have been recently reported. Radiation Therapy Oncology Group 0617 was a large phase III trial, which evaluated cetuximab, an EGFR-directed monoclonal antibody, in combination with chemoradiotherapy.8 The results showed no survival benefit for the addition of cetuximab. Phase I–II trials of EGFR tyrosine kinase inhibitors have been carried out in combination with radiotherapy for locally advanced NSCLC.9 However, further studies are warranted to confirm the outcome, biomarkers to select patients, and pathways to overcome drug resistance. The field of tumor immunology has seen an explosion of renewed interest over the past decade. The understanding of the interaction between the immune system and tumor growth has led to the development of modern immunotherapies, including cancer vaccines and immune checkpoint inhibitors. Checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4, programmed cell death 1, programmed cell death ligand-1, and others have shown clinical efficacy in a broad spectrum of tumor types. This has been selected as a breakthrough in both the scientific and medical fields. Preclinical data points strongly toward a strong synergy between radiotherapy and immune treatments. Early studies showed that radiotherapy could provoke important responses not only at irradiated tumor sites, but also at remote, non-irradiated tumor sites, which is the so-called “abscopal effect.” Recent work has elucidated the immune mechanisms underlying this effect, and has paved the way for developing combinations of immunotherapy with radiotherapy. It was believed that rational combinations of immunotherapy with radiotherapy could profoundly change the standard of care for many tumor types in the next decade.10, 11 However, several issues regarding dosage, timing, patient selection, and toxicity need to be resolved before the abscopal effect can become clinically relevant. Most importantly, a deep understanding of the immunological effects of radiotherapy is urgently required to design the next generation of therapeutic combinations. The development and application of molecular imaging techniques brings new opportunities, as well as challenges to precise radiotherapy. The delineation of biological target volume provides an opportunity for implementation of biological IMRT. Novel molecular imaging approaches are being developed and validated in many critical molecular pathways, such as hypoxia, angiogenesis, EGFR, and so on. However, we still do not know the best way to guide radiotherapy with these molecular images in certain cancers, either for target volume definition or prognosis stratification. Through precise target delineation using PET and magnetic resonance images, normal tissue toxicity can be reduced to a controllable extent; but how to translate precise target delineation into better local tumor control and even survival benefits requires more evidence. In general, personalized and precise radiotherapy is faced with many challenges including how to carry out precise target delineation and deliver a precise target dose. The development of precise radiotherapy requires a close combination of multiple disciplines, multiple technologies, and multi-imaging techniques to select candidate patients, define the target volume, and determine the individual dose. This requires the evidence-based guidance of anatomy, pathology, and molecular biology. More attention is required for basic and translational research, and more molecular typing studies should be carried out. High-quality and complete clinical specimen resources and patient follow-up databases are required to promote multidisciplinary clinical research. The new journal, Precise Radiation Oncology, will build a platform for researchers and physicians, especially radiation oncologists who focus on this rapidly innovative field. With multidisciplinary guidance, and the strong support of modern science and technology, precise radiotherapy will eventually be realized, incorporating radiobiology, bioinformatics, and molecular imaging.